At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 78 enrolled
Drug / intervention
BI 10773 low dose +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Oral Doses of BI 10773 as Tablets in Female and Male Patients With Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating BI 10773 low dose, placebo to BI 10773, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 78 participants across 3 sites.
Detailed Summary
Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartJan 2008
Primary CompletionApr 2008
TodayJul 2026
First PostedNov 15, 2007
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.6 years ago
Interventions
BI 10773 low dosedrug
placebo to BI 10773drug
BI 10773 medium dosedrug
BI 10773 high dosedrug